drugset / Trial / NCT00042510

Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

NCT00042510

Phase 2 Completed 103 enrolled Cancer Advances Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.

Timeline

Start
2000-08
Primary completion
2003-02
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject G17DT Immunogen Vaccine 500 ug
Background Cisplatin Other / unclassified 100 mg/m2 Intravenous
Background fluorouracil Small molecule 1000 mg/m2 Intravenous